QNCX
Quince Therapeutics, Inc.·Healthcare
1.15
4.167%(−0.05)
Close PriceLast Updated: — ET
52W L: $0.7952W H: $45.50
QNCX NEWS
seekingalpha.com
May 18
Quince Therapeutics, Inc. (QNCX) M&A Call Prepared Remarks Transcript
Quince Therapeutics, Inc. (QNCX) M&A Call Prepared Remarks Transcript
globenewswire.com
May 18
UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD
SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX) announced Phase 2a data evaluating LAM-001, an inhaled formulation of rapamycin (mTOR inhibitor), in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), presented at the American Thoracic Society (ATS) conference in Orlando. The Company recently acquired LAM-001 through its previously announced acquisition of Orphai Therapeutics, Inc., a clinical-stage biotechnology company developing LAM-001 to treat rare pulmonary diseases
globenewswire.com
May 18
Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline
SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX) announced it has acquired Orphai Therapeutics Inc., a clinical-stage biotechnology company. The acquisition brings Orphai's lead program LAM-001, an inhaled formulation of rapamycin (mTOR inhibitor), to treat rare pulmonary diseases, into Quince's pipeline. New Phase 2 data with LAM-001 were recently presented at the American Thoracic Society (ATS) conference in Orlando and are detailed in a separate press release also announced today.
globenewswire.com
May 18
Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD
SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX) announced Phase 2a data evaluating LAM-001, an inhaled formulation of rapamycin (mTOR inhibitor), in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), presented at the American Thoracic Society (ATS) conference in Orlando. The Company recently acquired LAM-001 through its previously announced acquisition of Orphai Therapeutics, Inc., a clinical-stage biotechnology company developing LAM-001 to treat rare pulmonary diseases
businesswire.com
Mar 30
Quince Therapeutics Settles Approximately $16.4 Million of Debt
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX) today announced the successful settlement of the company's outstanding obligations under its loan from the European Investment Bank (EIB) for a payment of $5.5 million. This marks a material milestone for Quince as the completion of the settlement resolves critical debt obligations and allows the company to advance its restructuring and evaluation of strategic alternatives aimed at maximizing shareholder valu.
defenseworld.net
Mar 28
Quince Therapeutics, Inc. (NASDAQ:QNCX) Given Average Recommendation of “Reduce” by Analysts
Shares of Quince Therapeutics, Inc. (NASDAQ: QNCX - Get Free Report) have earned a consensus recommendation of "Reduce" from the seven analysts that are presently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell rating and five have given a hold rating to the company. The average twelve-month target price among
